References:
  1. Ari Pelcovits and Rabin N. Acute Myeloid Leukemia: A Review.Rhode Island medical journal (2013). 2020;103.
  2. Toshiya Inaba and Akiko N. Monosomy 7: recent progress .[Rinsho ketsueki] The Japanese journal of clinical hematology. 2019;60:1020-1026 , pmid = 31597823.
  3. Berger LBaABaGLaGSaR. Monosomy-7 in childhood hemopoietic disorders.Leukemia. 1990;4:345-349 , pmid = 2201828.
  4. Marcin WWaSSSaCMN. Monosomy 7 in Pediatric Myelodysplastic Syndromes.Hematology/oncology clinics of North America. 2018;32:729-743 , pmid = 30047423 , publisher = Hematol Oncol Clin North Am.
  5. Tathagata Chatterjee and VPC. Childhood Myelodysplastic Syndrome ,.Symposium on Pediatric Oncology: Hemato-Oncology.
  6. Makia KMaTAHaARLaRERaQLaSNFaSM. Functional Consequence and Therapeutic Targeting of Cryptic ALK Fusions (ALK fus) in Monosomy7 AML.Blood. 2021;138:2357 , publisher = Content Repository Only!
  7. Palmer BHaRH. The role of the ALK receptor in cancer biology.Annals of Oncology. 2016;27.
  8. Cao Z, Gao Q, Fu M, Ni N, Pei Y, Ou WB. Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives (Review).Oncology Letters. 2018.
  9. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advance NSCLC. In: Elsevier Health 2013.
  10. Javier, Molina-Cerrillo JE-VaJJS-CaJPaMSR-GaIO-MaJT-JaACaTA-G. Tyrosine kinase receptors in oncology. International Journal of Molecular Sciences. 2020;21.
  11. Xue Du and Yun Shao and Hai Feng Qin and Yan Hong Tai and Hong Jun G. ALK-rearrangement in non-small-cell lung cancer (NSCLC).Thoracic Cancer. 2018;9.
  12. Kayo Takeoka and Atsuko Okumura and Yoshitomo Maesako and Takashi Akasaka and Hitoshi O. Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7. Cancer Genetics. 2015;208.
  13. Fei Fei Gu and Yong Zhang and Yang Yang Liu and Xiao Hua Hong and Jin Yan Liang and Fan Tong and Jing Song Yang and Li L. Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy. Journal of Hematology and Oncology. 2016;9.
  14. Liu W, Duan Q, Gong L, et al. A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.Investigational New Drugs. 2021;39(1):278-282.
  15. Jin L, Wang Y, Li S, Chen D, Zhao X. Novel PNPT1-ALK fusion variant exerted significant benefit to crizotinib in NSCLC. Lung Cancer. 2020;146:382-384.
  16. Yao Chen and Xiaochen Zhang and Qi Jiang and Bo Wang and Yina Wang and Yan J. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib. Lung Cancer. 2020;146:370-372.
  17. Mossé YP, Voss SD, Lim MS, et al. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study.Journal of Clinical Oncology. 2017;35(28):3215-3221.
  18. Felkai L, Bánusz R, Kovalszky I, et al. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors. Pathology & Oncology Research.2019;25(1):217-224.
  19. Yael PMaSDVaMSLaDRaCGMaEFaPAaKWaS. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A Children’s Oncology Group study.Journal of Clinical Oncology. 2017;35.
  20. Katherine Tarlock and Todd AAaYCWaRBGaRRaMRLaLPaTHaJJ. Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. Clinical Cancer Research. 2019;25.